Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.

Adlhoch, CorneliaDelgado-Sanz, ConcepciónCarnahan, AnnaSaraLarrauri, AmparoPopovici, OdetteBossuyt, NathalieThomas, IsabelleKynčl, JanSlezak, PavelBrytting, MiaGuiomar, RaquelRedlberger-Fritz, MonikaMaistre Melillo, JackieMelillo, Tanyavan Gageldonk-Lafeber, Arianne BMarbus, Sierk DO'Donnell, JoanDomegan, LisaGomes Dias, JoanaOlsen, Sonja J2023-01-312023-01-313670086810.2807/1560-7917.ES.2023.28.4.2200340http://hdl.handle.net/10029/626376enEUInfluenzaantiviral treatmentclinicepidemiologyfatal outcomehospitalinfluenza virusrisk factorssurveillanceEffect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.Article1560-7917Euro Surveill 2023;28(4):pii.2200340